Voyageur Secures Exclusive Rights To One Of The Worlds Rarest
Pharmaceutical
Minerals, Creating A New Era In Carbon Based Drug
Development
Calgary,
Alberta: May 11th,
2020 -- InvestorsHub
NewsWire -- Voyageur
Pharmaceuticals Ltd. (TSX.V:VM)
(USA:VYYRF) (the "Company" or
"Voyageur") is pleased to announce it has signed an LOI with an
established international mining company (the "Counterparty") that
has developed a low cost method to extract the natural occurring
carbon molecule, C-60 to C-90, from large
natural-occurring fullerene
resources.
The technology to extract C-60 from natural
fullerene deposits is ground-breaking and a first in this industry.
“Voyageur will be the first company to be able to mass produce C-60
at a low cost, allowing for multiple drug products to be
developed,” states Brent Willis, CEO of
Voyageur Pharmaceuticals.
“The barriers for C-60 based drugs has now been
broken, which opens up the industry to develop new effective drugs
and health care products on an economic scale,” continues
Willis.
The API, C-60, is a natural, highly effective
super antioxidant, like more common antioxidants (Vitamin C,
Vitamin A and Selenium). It scavenges toxic free radicals but it
stands out as a notable anti-aging innovation because it
selectively scavenges the reactive oxygen species that do the most
damage to humans as opposed to just working by osmosis like a
normal antioxidant. The anti-aging properties are exciting, as
studies in animals have shown the potential to significantly extend
life span and to slow the aging process.
Voyageur has begun work on its first C-60 product,
C-60X, an immune system booster, natural health product, for daily
consumption. Voyageur is creating a C-60 R&D Therapeutics
division that will be focused on developing natural health products
and drugs. For early cash flow, Voyageur will utilize our
Calgary-based manufacturing partners for natural health product
sales.
Highlights
of C-60 Medical Applications
-
Radio
Graphic Contrast Media-
Allowing drugs to be safer, more effective by using C-60 to be a
transport system for iodine and gadolinium
drugs.
-
Anti
Viral –
Antiretroviral therapy (Influenza, HIV, HSV, CMV (1)), Studies show
how C-60 has an ability to supress viruses, minimising their
effects on the body.
-
Anti-bacterial
inhibition (Antibiotics)-studies prove that C-60
can be used as an antibiotic.
-
Anti
Aging-
Batti study showed that life span of rats almost
doubled.
-
Photosensitizers
and Sonosensitizers (Cancer treatments). C-60 has
been proven to work as a mechanism in photodynamic therapy to
destroy cancer cells.
-
Antioxidant
Immune System Enhancer (Daily supplements for
improved health)- C-60 is currently sold as an immune supplement.
Voyageur is creating C-60X, an immune system daily supplement to
help people increase their immune system
function.
-
Antitumor
and Antimetastatic Agent Vaccines. Potential for
vaccine development.
-
EMFs
Endohedral metallofullerenes (drug transport
systems) C-60 can be used to transport drugs to the source of the
disease.
-
Cardiovascular
Health, studies have shown that c-60 improves
cardiovascular health
-
Anti-Inflammatory
Agents
-
Sunscreen-Protection
from Radiation-Induced Injury, Ionizing Radiation, and UVA, it
helps repair damaged skin.
-
Athletic
Performance Enhancement- Studies report higher athletic
performance and increased recovery from muscle strain due to
intense work outs.
"The difficulty in processing of
fullerenes has presented a major problem in the search for
medicinal applications. This is the breakthrough
that our partner
has recently overcome.
The
patent-pending technology, that can recover economic & high
volumes of C-60 from natural fullerene mineral ores, is a game
changer. This opens the door for Voyageur to become the only
company to have the capability to develop and mass produce C-60
based drugs and natural health products at a low cost & high
volume,” says Willis.
Voyageur plans to develop low cost
C-60 radiographic contrast drugs, which encapsulate iodine,
gadolinium, and other potential molecules. By utilizing C-60, we
may be able to enhance the performance and create the safest
radiographic contrast media in the marketplace. Studies have shown
that MRI C-60 gadolinium contrast media has a gain of a 500-fold
sensitivity on intravital MR Contrast Agents.
Essentially, a carbon-60 molecule is
comprised of 60 carbon atoms which are arranged in a unique shape
that can be thought of as a 'carbon cage' (like a soccer ball).
This sphere makes it possible to be a carrier of other molecules
creating a protective shield, allowing C-60 to be an excellent drug
delivery vehicle in radiology and healthcare.
“This drug delivery system is quite unique to the
pharmaceutical industry and our company is proud to begin the
innovative steps to develop unique new delivery systems,” states
Willis.
It has long been known that
effective delivery systems are of paramount importance in promoting
drug efficacy. “This is not only a major milestone for our Company,
but potentially a major breakthrough for the entire healthcare
industry,” continues Willis.
The significance of the technological
breakthrough, to extract natural fullerene from rock, may well pave
the way for a low-cost evolution in the carbon-based health care
market. Voyageur is the first company to begin to break down the
barrier to market. The C-60 therapeutics division will enhance our
Company’s ability to become more competitive in the radiographic
contrast market and become a leader in the C-60 drug & natural
health sector. Fullerene is a gateway for Voyageur to become a
leader in a new and exciting carbon medicine field. We will
continue to build our From The Earth To The
Bottle strategy, to become a fully-integrated
competitive force in the API mineral based pharmaceutical
industry.”
The signed LOI for supply exclusivity will allow
Voyageur to produce low cost & high-volume natural carbon-60
API for the pharmaceutical industry. This would allow Voyageur to
be fully integrated in the C-60 market and become the only low-cost
producer of fullerene based health care products. Voyageur is
adding C-60 to its portfolio of active pharmaceutical ingredients
(API) minerals for use in the radiographic contrast media markets.
There are multiple applications for Fullerene based nano medicines
in the healthcare industry, which Voyageur will further research
and develop.
Due to confidentiality and pending
patents, Voyageur cannot disclose at this time, the identity of the
Counterparty.
About
Voyageur
Voyageur Pharmaceuticals Ltd. is
Canadian public company listed on the TSX Venture Exchange under
the trading symbol VM. Voyageur is focused on the development of
barite, iodine, and fullerene Active Pharmaceutical Ingredient
(API) minerals. The near-term focus is developing barium, iodine
radio-contrast products and fullerene-based pharmaceutical
products.
Voyageur’s goal is to initially
generate the positive cash flow from operations using third party
GMP pharmaceutical manufacturers. Ultimately, Voyageur has plans to
build all the required infrastructure to become 100%
self-sufficient with all manufacturing.
Voyageur owns a 100% interest in three
barium sulfate (barite) projects including two properties suitable
in grade for the industrial barite marketplace, including interests
in a high-grade iodine, lithium & bromine brine project located
in Utah, USA.
Voyageur is moving forward with its
business plan of becoming the only fully integrated company in the
radio-contrast medical field, by controlling all primary input
costs under the motto of:
"From the Earth to the
Bottle"
For
Further Media Information or to set up an interview, please
contact:
Reader Advisory
Neither the TSXV nor its Regulation Services
Provider (as that term is defined in the policies of the TSXV)
accepts responsibility for the adequacy or accuracy of this news
release.
Cautionary Note Regarding Forward-Looking
Statements
This news release contains certain statements or
disclosures relating to the Company that are based on the
expectations of its management as well as assumptions made by and
information currently available to the Company which may constitute
forward-looking statements or information ("forward-looking
statements") under applicable securities laws. All such statements
and disclosures, other than those of historical fact, which address
activities, events, outcomes, results, or developments that the
Company
anticipates may or will occur in the future (in
whole or in part) should be considered forward-looking statement
and undue reliance should not be placed on any such statements. In
some cases, forward-looking statements can be identified by the use
of the words "will", "intends", “believes”, “expects”, forecasts”,
"anticipates", "plans" and similar
expressions.
In particular, but without limiting the foregoing,
this news release contains forward-looking statements pertaining to
the following, the certainty of the disclosed LOI being made into a
formal binding agreement; the ability of Voyageur to integrate
fullerene into marketable pharmaceutical and healthcare
markets; the feasibility and expectation of the Company to
bring into production those mining assets it has an interest
in; the experience of management and directors of Voyageur and its
pharmaceutical
manufacturing partners to
execute on its business plan and that of its joint venture company;
the economics and risks associated with its business plan;
future operations and strategies for development, sales and
distribution of mineral and pharmaceutical product;; the Company’s
ability to successfully penetrate either domestic or foreign
pharmaceutical markets; the amount, quality and cost of supply of
active pharmaceutical ingredients for potential pharmaceutical
products; the ability for Voyageur to meet its joint venture
obligations; anticipated registrations with Health Canada or
similar foreign bodies for various pharmaceutical products the
Company plans to develop, produce and sell; and the ability of the
Company to attract investment capital to fund operations and
capital expenditures.
The forward-looking statements contained in this
news release are made as of the date hereof and the Company
undertakes no obligations to update publicly or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, unless so required by applicable
securities laws.
Source Information:
https://www.ncbi.nlm.nih.gov/pubmed/23785493/
https://phys.org/news/2019-09-fullerene-compounds-virus-infections-hiv.html,
https://c60-france.com/media_upload/C60-Fullerene-nano-particles-Inhibit-HIV-Replication.pdf
https://www.sesres.com/carbon-60-c60-powder/#buy_c60
https://www.sciencedirect.com/science/article/pii/S0142961212003237
https://www.hindawi.com/journals/jnm/2015/565638/
https://en.wikipedia.org/wiki/Fullerene
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2880842/
https://www.sciencedirect.com/science/article/pii/S0142961212003237
Mitsubishi
https://www.azonano.com/article.aspx?ArticleID=47
https://pubs.acs.org/doi/full/10.1021/es801869m
https://phys.org/news/2020-03-scientists-water-soluble-fullerene-compounds-medicine.html
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676811/
https://pubs.acs.org/doi/10.1021/acsanm.9b01698
Voyageur Pharmaceuticals (TSXV:VM)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
Voyageur Pharmaceuticals (TSXV:VM)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024
